Talapro-3 could help move Talzenna into earlier prostate cancer.
ApexOnco Front Page
Recent articles
Single, double and even triple-payload ADCs will be presented at the meeting.
The restructured biotech’s new lead project enters phase 1.
The company will imminently start its third pivotal trial of PF-08634404.
The company ditches lorigerlimab in prostate cancer.
But the Day One deal is still 29% below where the shares stood at the start of this year.
The Rainfol-04 trial in platinum-sensitive ovarian cancer will start next year.
New detalimogene bladder cancer data send the minnow’s stock up 47%.
